Get intelligentvalue.com

Own it today or select a payment plan

Buy Now$3,879Payment Plan$325/mo

Secured by Stripe

Premium Domain Name

intelligentvalue.com

is available for purchase

51 views

Visitors from

US 54%·

AU 32%·

IN 7%·

GB 2%·

FR 2%

Perfect for

Financial Consulting Technology Startups Educational Services Economic Forecasting E-commerce Solutions Business Analytics Artificial Intelligence Solutions Investment Advisory Strategic Planning Market Research

Unlock the potential of 'intelligentvalue.com', a premium domain that embodies sophistication and expertise in investment advisory and financial consulting. Perfect for businesses in artificial intelligence solutions, market research, and strategic planning, this memorable domain conveys a strong branding message that resonates with clients seeking innovative and data-driven insights. Elevate your presence in the competitive landscape with a digital identity that signifies intelligence, value, and forward-thinking solutions.

Safe & Secure

Protected transactions with Stripe

Fast Transfer

Domain transferred within 24 hours

Flexible Payments

Interest-free payment plans available

Mydecine Innovations Group develops novel compounds for treating mental health

February 07, 2022 at 13:52 PM EST

ⓘ This article is third-party content and does not represent the views of this site. We make no guarantees regarding its accuracy or completeness.

Mydecine Innovations Group is developing novel compounds to treat people's mental health and addiction problems.

Mydecine Innovations Group™ (NEO: MYCO) (OTC: MYCOF) (FSE:0NFA) is a digital technology and biotechnology organization that develops innovative novel compounds that help in treating mental health and addiction. It uses high-class technology and drug development infrastructure for developing these second and third-generation compounds.

The medical and scientific advisory board is researching and developing novel compounds, therapies, drug delivery systems, and psychedelic derived therapeutics.

Mydecine Innovations Group has signed a Letter of Intent or LOI with Maya. The two companies will jointly develop a novel digital therapeutics platform. It will help Mydecine for enhancing the effectiveness of the treatment by pairing the DTx to the digital health platform Mindleap Health. It will be along with the company's medicine-based treatments for achieving a triple approach.

The company also announced that they have finished a model of the psychedelic serotonin receptor 5-HT2A for use in the AI-driven drug discovery program. With this new model, they will determine the novel compounds that can increase binding affinity. This will lead to creating second and third-generation psychedelic molecules for medicinal purposes.

Innovation and advancement have been made in treating cancer, diabetes, and other diseases. But similar steps have not been taken in treating mental health disorders like PTSD and depression. With the compounds developed by Mydecine, there is a growing chance of treating mental health disorders properly.

The company has signed a five-year research agreement with Johns Hopkins University School of Medicine. With this, conditions like anxiety and depression can be combated.

They also announced the launch of a phase 2/3 smoking cessation clinical trial with Johns Hopkins University. With such associations, Mydecine is looking forward to changing mental health and addiction treatment among individuals.

Learn more at: https://smallcapexclusive.com/mydecine-otcmycof-neomyco-is-undervalued-mydecine-has-an-incredible-pps-target-take-a-look

About Mydecine Innovations Group:

Mydecine Innovations Group™ (NEO: MYCO) (OTC: MYCOF) (FSE:0NFA) is a digital technology and biotechnology organization that develops innovative novel compounds that help treat different mental health conditions and addiction.

For more information, visit https://www.mydecine.com/investors/company-information

Disclaimer: This article is purely for informational purposes and is not a recommendation in any way to buy or sell stocks.

Media Contact
Company Name: Mydecine Innovations Group
Contact Person: Investor Relations
Email: Send Email
Country: Canada
Website: www.mydecine.com